New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
New to The Street, a leading U.S. business television platform, has renewed its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company. The new series includes broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.
Acurx Pharmaceuticals will be featured on New to The Street's national television broadcasts, highlighting the company's latest developments and leadership in addressing critical bacterial infections through innovative antibiotics. The coverage will air across major networks, enhancing Acurx's visibility in the biopharmaceutical sector.
The partnership also includes targeted earned media placements and outdoor advertising support, featuring billboard placements in strategic locations like Times Square and the Financial District. The media series is set to begin airing immediately in 2024, with outdoor and earned media elements running concurrently to maximize audience reach.
New to The Street, una delle principali piattaforme televisive di affari negli Stati Uniti, ha rinnovato la sua partnership mediatica con Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), una società biofarmaceutica in fase avanzata. La nuova serie include interviste televisive, posizionamenti media guadagnati e una campagna pubblicitaria all'aperto completa.
Acurx Pharmaceuticals sarà presente nelle trasmissioni nazionali di New to The Street, mettendo in evidenza gli ultimi sviluppi dell'azienda e il suo ruolo di leadership nell'affrontare gravi infezioni batteriche attraverso antibiotici innovativi. La copertura andrà in onda su importanti reti, aumentando la visibilità di Acurx nel settore biofarmaceutico.
La partnership include anche posizionamenti media guadagnati mirati e supporto pubblicitario all'aperto, con affissioni in luoghi strategici come Times Square e il Distretto Finanziario. La serie mediatica inizierà a essere trasmessa immediatamente nel 2024, con elementi pubblicitari esterni e media guadagnati che correranno in parallelo per massimizzare la portata del pubblico.
New to The Street, una de las principales plataformas de televisión empresarial en EE. UU., ha renovado su asociación mediática con Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), una compañía biofarmacéutica en etapas avanzadas. La nueva serie incluye entrevistas en televisión, colocaciones de medios ganados y una completa campaña publicitaria al aire libre.
Acurx Pharmaceuticals aparecerá en las transmisiones nacionales de New to The Street, destacando los últimos desarrollos de la compañía y su liderazgo en el tratamiento de infecciones bacterianas críticas a través de antibióticos innovadores. La cobertura se transmitirá en las principales redes, mejorando la visibilidad de Acurx en el sector biofarmacéutico.
La asociación también incluye colocaciones de medios ganados específicas y apoyo publicitario al aire libre, con vallas publicitarias en ubicaciones estratégicas como Times Square y el Distrito Financiero. La serie mediática comenzará a transmitirse de inmediato en 2024, con elementos de publicidad exterior y medios ganados funcionando simultáneamente para maximizar el alcance del público.
New to The Street는 미국의 주요 비즈니스 텔레비전 플랫폼으로, Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)와의 미디어 파트너십을 갱신했습니다. 이 새로운 시리즈에는 방송 텔레비전 인터뷰, 획득한 미디어 배치 및 포괄적인 옥외 광고 캠페인이 포함됩니다.
Acurx Pharmaceuticals는 New to The Street의 전국 방송에 출연하여 혁신적인 항생제를 통해 심각한 박테리아 감염 문제를 해결하는 회사의 최신 발전과 리더십을 강조할 것입니다. 이 보도는 주요 네트워크에서 방영되어 Acurx의 생명공학 부문에서의 가시성을 높일 것입니다.
이 파트너십은 타겟팅된 획득한 미디어 배치 및 옥외 광고 지원도 포함되며, 타임스 스퀘어와 금융 지구와 같은 전략적인 위치에 옥외 광고가 게재됩니다. 이 미디어 시리즈는 2024년 즉시 방송될 예정이며, 옥외 및 획득한 미디어 요소는 동시에 운영되어 청중 도달 범위를 극대화합니다.
New to The Street, une plateforme télévisée d'affaires de premier plan aux États-Unis, a renouvelé son partenariat médiatique avec Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), une société biopharmaceutique en phase avancée. La nouvelle série comprend des interviews télévisées, des placements médiatiques acquis et une campagne de publicité extérieure complète.
Acurx Pharmaceuticals sera présenté dans les émissions nationales de New to The Street, mettant en lumière les derniers développements de l'entreprise et son leadership dans le traitement des infections bactériennes critiques grâce à des antibiotiques innovants. La couverture sera diffusée sur les principales chaînes, améliorant ainsi la visibilité d'Acurx dans le secteur biopharmaceutique.
Le partenariat comprend également des placements médiatiques ciblés et un soutien à la publicité extérieure, avec des panneaux publicitaires dans des lieux stratégiques tels que Times Square et le quartier financier. La série médiatique commencera à être diffusée immédiatement en 2024, avec des éléments de publicité extérieure et des médias acquis fonctionnant en parallèle pour maximiser la portée du public.
New to The Street, eine führende US-amerikanische Geschäftstelevisionsplattform, hat ihre Medienpartnerschaft mit Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), einem biopharmazeutischen Unternehmen in der Spätphase, erneuert. Die neue Serie umfasst Fernsehinterviews, erworbene Medienplatzierungen und eine umfassende Außenwerbungskampagne.
Acurx Pharmaceuticals wird in den nationalen Fernsehsendungen von New to The Street zu sehen sein, wobei die neuesten Entwicklungen des Unternehmens und die Führungsrolle im Kampf gegen kritische bakterielle Infektionen durch innovative Antibiotika hervorgehoben werden. Die Berichterstattung wird über wichtige Netzwerke ausgestrahlt und erhöht somit die Sichtbarkeit von Acurx im biopharmazeutischen Sektor.
Die Partnerschaft umfasst auch gezielte Platzierungen in den Medien und Unterstützung durch Außenwerbung, einschließlich Plakatierungen an strategischen Standorten wie Times Square und dem Finanzdistrikt. Die Medienreihe wird 2024 sofort ausgestrahlt, wobei die Außen- und Medienplatzierungen parallel laufen, um die Reichweite des Publikums zu maximieren.
- Renewed media partnership with New to The Street, a leading U.S. business television platform
- Multi-platform exposure through national television broadcasts, earned media, and outdoor advertising
- Enhanced brand visibility and reputation within the biopharmaceutical sector
- Strategic billboard placements in high-traffic areas like Times Square and the Financial District
- None.
The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The Street, one of the leading U.S. business television platforms, is pleased to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company. The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.
As part of this extended partnership, Acurx Pharmaceuticals will be featured on New to The Street's national television broadcasts. The series will spotlight the company's latest developments, milestones, and its leadership in addressing critical bacterial infections through innovative antibiotics. The coverage will air across major networks, enhancing Acurx Pharmaceuticals' brand visibility and reputation within the biopharmaceutical sector.
In addition to broadcast television, the series will benefit from targeted earned media placements, amplifying exposure through high-visibility press outlets and digital media channels. Complementing the broadcast and earned media strategy, Acurx Pharmaceuticals will also receive support from New to The Street's outdoor advertising platforms, including iconic billboard placements in strategic locations such as Times Square and the Financial District.
"We are thrilled to continue our collaboration with Acurx Pharmaceuticals as they progress in their mission to combat difficult-to-treat bacterial infections," said Vince Caruso CEO of New to The Street. "Our multi-platform approach-combining national television, earned media, and outdoor campaigns-ensures their message reaches the right audience at scale."
The media series is set to begin airing immediately, 2024, with outdoor and earned media elements running concurrently to maximize audience reach.
For more information about New to The Street and its upcoming programming, visit http://www.NewtoTheStreet.com
About New to The Street
New to The Street is a leading business television program, airing on major U.S. networks such as FOX Business and Bloomberg through sponsored programming. With over 15 years of experience, the platform delivers in-depth interviews with CEOs and executives from high-growth companies across various industries.
Following the national broadcasts, New to The Street amplifies its reach by sharing interviews across its robust social media channels, including nearly 2 million YouTube subscribers and extensive audiences on X (formerly Twitter), LinkedIn, and Instagram. The platform's earned media campaigns consistently secure over 50 pickups weekly across top-tier networks like ABC, NBC, and CBS, providing further exposure on morning and evening business news segments.
Through its recent collaboration with AccreditedEvents.com, New to The Street offers clients the opportunity to connect with top-tier family offices, retail investors, and private equity firms at exclusive NYC non-deal roadshow events-positioning companies directly in front of key investors.
For more information, visit http://www.NewtoTheStreet.com
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Contact Information
Monica Brennan
Head of Operations
monica@newtothestreet.com
Related Images
|
SOURCE: New to The Street
View the original press release on accesswire.com
FAQ
What is the new media partnership between Acurx Pharmaceuticals (NASDAQ:ACXP) and New to The Street?
When will the new media series for Acurx Pharmaceuticals (NASDAQ:ACXP) begin airing?
Where will the outdoor advertising for Acurx Pharmaceuticals (NASDAQ:ACXP) be displayed?
What is the focus of Acurx Pharmaceuticals' (NASDAQ:ACXP) feature on New to The Street's broadcasts?
